About this trial
Congenital heart disease (CHD) is defined as functional or anatomical abnormalities of the heart and major intrathoracic vessels present at birth. Impaired responses to exercise in individuals with CHD reduce exercise capacity and increase long-term mortality risk. Today, the growing population of adults with congenital heart disease (ACHD) faces chronic issues stemming from congenital abnormalities, along with muscle strength loss and a decline in activities of daily living. Once the planned treatments in this project proposal are implemented and data are obtained (especially if these data support the hypotheses), the treatment protocols applied in this study and their effects will be considered alongside the current treatment plans for individuals with CHD who experience muscle strength loss and disease-related impairment. With new treatment programs, this study aims to reduce disease-related muscle strength loss, improve disease-related outcomes, and enhance quality of life.
Eligibility criteria
Qualifiers
Diagnosis of congenital heart disease
Aged between 18 and 45 years
Being informed about the study and providing written consent to participate
Clinical stability has been achieved in the patients
Disqualifiers
Having additional cardiovascular, neurological, orthopedic, or any other systemic diseases
Being classified as high risk (severe systolic dysfunction, moderate/severe elevated pulmonary artery pressure, significant arrhythmic burden, malignant arrhythmia, etc.)
Not suitable for cognitive, psychological, and mental assessments
Undergoing a surgery other than heart surgery
Trial design
Treatments tested in this trial
- Hospital-Based Resistance Training
- Home-Based Resistance Training